10-K: Owlet, Inc. Reports Record Revenue and Improved Profitability in 2024 10-K Filing

Owlet, Inc.'s 2024 10-K filing highlights record revenue, improved profitability, and strategic advancements in the pediatric health technology sector.

Summary

• Owlet, Inc.'s 10-K filing for the year ended December 31, 2024, reveals significant progress in revenue and profitability.
• The company achieved record revenue of $78.06 million, a 44.5% increase compared to 2023.
• Gross profit also saw a substantial rise, reaching $39.31 million, with a gross margin of 50.4%.
• Owlet improved its net loss by $20.4 million compared to the previous year.
• Adjusted EBITDA improved by $14.3 million, with positive adjusted EBITDA reported in the final three quarters of 2024.
• The company launched Dream Sock in the European Union and the United Kingdom, expanding its global presence to 26 countries.
• Owlet also introduced its Owlet360 subscription service, enhancing its pediatric health platform.
• The FDA marketing authorizations for Dream Sock and BabySat are expected to drive further adoption of Owlet's products.
• The company is focused on expanding into healthcare distribution and securing insurance reimbursement for BabySat.
• Despite these achievements, the company acknowledges substantial doubt about its ability to continue as a going concern without additional funding.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive aspects such as revenue growth and FDA approvals, the going concern warning and ongoing legal issues temper the overall outlook.

Positives

• Record revenue and improved gross profit margins indicate strong market demand and efficient operations.
• Positive adjusted EBITDA in the final three quarters of 2024 suggests a path towards profitability.
• FDA marketing authorizations for Dream Sock and BabySat enhance credibility and market access.
• Global expansion and the launch of Owlet360 demonstrate strategic growth initiatives.
• The company has a large data set of infant health and sleep information, which can be leveraged for future product development and services.

Negatives

• The company has an accumulated deficit of $268.2 million as of December 31, 2024.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company relies on a limited number of retailers for a substantial portion of its sales.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company is involved in ongoing legal proceedings, including securities class action lawsuits.

Risks

• The company has a limited operating history and has not been profitable to date.
• The company may need to raise additional capital in the future, which may not be available on acceptable terms.
• The company relies on mobile applications to function and is dependent on Apple's App Store and Google Play Store.
• The company currently relies on single manufacturers for the assembly of its Dream Sock, Smart Sock, BabySat products and Owlet Cam.
• The company faces increasing competition from other companies, many of which have substantially greater resources.
• The company is subject to risks associated with its distributors and retailers Owlet product inventories and sell-through to end consumers.
• The company is subject to a series of risks regarding climate change.
• The company is subject to a number of risks related to the credit extended by our manufacturing providers.

Future Outlook

The company expects the FDA marketing authorizations of BabySat and Dream Sock to accelerate product adoption and position Owlet as the preferred pediatric data monitoring platform.

Management Comments

• The FDA marketing authorizations for both Dream Sock and BabySat mark a significant moment for the pediatric category and solidify the trust of consumers and healthcare professionals alike.
• We are committed to building a strong foundation for sustainable growth as we move forward.

Industry Context

Owlet competes in the consumer digital health monitoring space for infants, facing competition from established players like VTech, Nanit, Masimo, and Hubble. The company's FDA clearances provide a competitive advantage and set a high regulatory bar for new entrants.

Comparison to Industry Standards

• Owlet's pioneering achievement of obtaining the first de novo authorization for at-home monitoring without the need for a prescription underscores our trailblazing efforts and helps set a high regulatory bar for new entrants in the space.
• Competitors include VTech, Nanit, Masimo and Hubble.
• Nanit offers a line of video monitors and non-FDA cleared integrated breathing wrap wearable.
• Masimo is primarily focused on patient monitoring solutions for hospital and clinical settings.
• Hubble delivers a variety of low-cost sound and video monitors, including options with non-FDA cleared wearable health monitoring capabilities.

Legal Proceedings

• In November 2021, two putative class action complaints were filed against the Company in the U.S. District Court for the Central District of California, the first captioned Butala v. Owlet, Inc. , Case No. 2:21-cv-09016, and the second captioned Cherian v. Owlet, Inc. , Case No. 2:21-cv-09293.
• On August 26, 2024 and October 3, 2024, investors filed in the U.S. District Court for the Central District of California, derivatively on behalf of the Company, complaints asserting claims for violations of Section 14(a) of the Exchange Act, as well as state law claims, including breach of fiduciary duty, unjust enrichment and waste of corporate assets.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by cost reduction measures if additional funding is not secured.
• Customers may benefit from new products and services resulting from strategic growth initiatives.
• Creditors face increased risk due to the company's going concern uncertainty.

Next Steps

• The company will continue to develop its software and data to bring additional solutions into the home.
• The company will remain focused on commercializing its Dream Sock and BabySat devices.
• The company will continue to expand into international and new geographic markets.
• The company will continue to pursue additional marketing authorizations from applicable regulatory authorities and certification from notified bodies.

Key Dates